Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia

Neuropsychopharmacology

Volumn 38, Issue 7, 2013, Pages 1245-1252

  Jarskog, L Fredrik ^a   Dong, Zhengchao ^b   Kangarlu, Alayar ^b   Colibazzi, Tiziano ^b   Girgis, Ragy R ^b   Kegeles, Lawrence S ^b   Barch, Deanna M ^c   Buchanan, Robert W ^d   Csernansky, John G ^e   Goff, Donald C ^f   Harms, Michael P ^c   Javitt, Daniel C ^b   Keefe, Richard Se ^g   McEvoy, Joseph P ^g   McMahon, Robert P ^d   Marder, Stephen R ^h   Peterson, Bradley S ^b   Lieberman, Jeffrey A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cognition; MRS; neuroprotective; neurotrophic; proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; DAVUNETIDE; N ACETYLASPARTIC ACID; PLACEBO;

ADULT; ALERTNESS; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FUNCTIONAL STATUS; HUMAN; LEARNING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE FRONTAL GYRUS; NEUROIMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOCIAL COGNITION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; CHOLINE; COGNITION; CREATINE; FEMALE; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PREFRONTAL CORTEX; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84878556531     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.23     Document Type: Article

References (35)

1. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF et al (2001). The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.
2. Bertolino A, Sciota D, Brudaglio F, Altamura M, Blasi G, Bellomo A et al (2003). Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder. Am J Psychiatry 160: 483-489.
3. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V et al (2004). Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161: 742-744.
4. Brugger S, Davis JM, Leucht S, Stone JM (2011). Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol Psychiatry 69: 495-503.
5. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ et al (2006). Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 31: 751-756.
6. Bustillo JR, Rowland LM, Lauriello J, Petropoulos H, Hammond R, Hart B et al (2002). High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia. Am J Psychiatry 159: 130-133.
7. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R et al (2000). Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 10: 1078-1092.
8. Dong Z, Dreher W, Leibfritz D (2006). Toward quantitative shortecho-time in vivo proton MR spectroscopy without water suppression. Magn Reson Med 55: 1441-1446.
9. Ertugrul A, Volkan-Salanci B, Basar K, Karli Oguz K, Demir B, Ergun EL et al (2009). The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Res 174: 121-129.
10. Fujimoto T, Nakano T, Takano T, Takeuchi K, Yamada K, Fukuzako T et al (1996). Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol Psychiatry 40: 14-18.
11. Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM et al (1998). Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry 65: 446-453.
12. Glantz LA, Lewis DA (1997). Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. Arch Gen Psychiatry 54: 943-952.
13. Glantz LA, Lewis DA (2000). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57: 65-73.
14. Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I (2012). Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat 8: 85-93.
15. Gozes I (2011). Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate. Peptides 32: 428-431.
16. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W et al (1998). A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 55: 145-152.
17. Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF et al (2012). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res 136: 25-31.
18. Lentz MR, Kim JP, Westmoreland SV, Greco JB, Fuller RA, Ratai EM et al (2005). Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 235: 461-468.
19. Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I (2010). NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse-a microtubule-deficient model of schizophrenia. Peptides 31: 1368-1373.
20. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007). N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131.
21. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A et al (2007). Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res 41: 625-634.
22. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM et al (2003). Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res 144: 83-90.
23. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998). Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55: 215-224.
24. Sajja BR, Wolinsky JS, Narayana PA (2009). Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 19: 45-58.
25. Selemon LD, Rajkowska G, Goldman-Rakic PS (1995). Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 52: 805-818.
26. Selemon LD, Rajkowska G, Goldman-Rakic PS (1998). Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J Comp Neurol 392: 402-412.
27. Shenton ME, Whitford TJ, Kubicki M (2010). Structural neuroimaging in schizophrenia: from methods to insights to treatments. Dialogues Clin Neurosci 12: 317-332.
28. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR (2005). Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci 25: 225-238.
29. Soher BJ, Doraiswamy PM, Charles HC (2005). A review of 1H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am 15: 847-852 x.i.
30. Steen RG, Hamer RM, Lieberman JA (2005). Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 30: 1949-1962.
31. Thompson PM, Vidal C, Giedd JN, Gochman P, Blumenthal J, Nicolson R et al (2001). Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 98: 11650-11655.
32. Van Haren NE, Pol HE, Schnack HG, Cahn W, Brans R, Carati I et al (2008). Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry 63: 106-113.
33. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z et al (2007). Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther 323: 438-449.
34. Walterfang M, Velakoulis D, Whitford TJ, Pantelis C (2011). Understanding aberrant white matter development in schizophrenia: an avenue for therapy? Expert Rev Neurother 11: 971-987.
35. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET (2000). Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 157: 16-25.